Orudis

Migraine, Migraine Disorders, Pain + 9 more
Treatment
5 FDA approvals
20 Active Studies for Orudis

What is Orudis

KetoprofenThe Generic name of this drug
Treatment SummaryKetoprofen is a pain reliever and fever reducer that belongs to a class of drugs called nonsteroidal anti-inflammatory agents (NSAIAs). It helps reduce inflammation, pain, and fever.
Ketoprofenis the brand name
image of different drug pills on a surface
Orudis Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ketoprofen
Ketoprofen
1993
51

Approved as Treatment by the FDA

Ketoprofen, also known as Ketoprofen, is approved by the FDA for 5 uses such as Postoperative Pain and Postoperative pain .
Postoperative Pain
Helps manage Postoperative pain
Postoperative pain
Helps manage Postoperative pain
Post Partum Pain
Helps manage Post Partum Pain
Ankylosing Spondylitis (AS)
Helps manage Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Helps manage Ankylosing Spondylitis (AS)

Effectiveness

How Orudis Affects PatientsKetoprofen is a type of medicine (nonsteroidal anti-inflammatory agent) that is used to reduce pain and fever. It works by blocking the production of certain chemicals that are responsible for inflammation, swelling, and pain. It is commonly used to treat rheumatoid arthritis, osteoarthritis, menstrual cramps, and other moderate pain.
How Orudis works in the bodyKetoprofen works by blocking an enzyme called cyclooxygenase-2 (COX-2). This enzyme is involved in producing hormones that cause pain, fever, and inflammation. Blocking the enzyme reduces these hormones, which helps reduce pain and inflammation. It can also help lower fever. It might also prevent the body from making other hormones that can cause upset stomach and ulcers. Ketoprofen also helps stabilize cell walls and reduces the amount of a hormone that causes swelling. This can help reduce fever by increasing blood flow and allowing the body to cool off.

When to interrupt dosage

The measure of Orudis is contingent upon the diagnosed condition, such as Sprains, Ankylosing Spondylitis and Pain. The amount of dosage may differ, in light of the application technique (e.g. Capsule, extended release - Oral or Tablet, delayed release) featured in the table below.
Condition
Dosage
Administration
Ankylosing Spondylitis
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Pain
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Rheumatoid Arthritis
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Sprains and Strains
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Osteoarthritis
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Mild pain
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Muscle Strain
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Migraine
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Migraine Disorders
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Postoperative Pain
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Primary Dysmenorrhoea
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical
Post Partum Pain
, 50.0 mg, 75.0 mg, 200.0 mg, 100.0 mg, 150.0 mg, 0.05 mg/mg, 25.0 mg, 3.35 mg/mg, 0.5525 mg/mg
, Capsule, Oral, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Rectal, Suppository - Rectal, Suppository, Topical, Tablet, extended release - Oral, Kit, Tablet, Tablet, extended release, Powder - Topical

Warnings

Orudis has two contraindications and should be avoided when encountering the conditions presented in the following table.Orudis Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Coronary Artery Bypass Grafting
Do Not Combine
There are 20 known major drug interactions with Orudis.
Common Orudis Drug Interactions
Drug Name
Risk Level
Description
Allantoin
Major
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Allantoin.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Ketoprofen.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Ketoprofen.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Ketoprofen.
Dabrafenib
Major
The metabolism of Dabrafenib can be decreased when combined with Ketoprofen.
Orudis Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats has been found to be 62.4mg/kg when taken orally. Symptoms of overdosing may include drowsiness, vomiting, and stomach pain. Common side effects are usually mild and affect the digestive system, such as feeling bloated, nausea, diarrhea, stomach pain, constipation, and gas.

Orudis Novel Uses: Which Conditions Have a Clinical Trial Featuring Orudis?

153 active investigations are currently evaluating the potential of Orudis to alleviate Post Partum Pain, Rheumatoid Arthritis and Ankylosing Spondylitis.
Condition
Clinical Trials
Trial Phases
Postoperative Pain
19 Actively Recruiting
Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable
Rheumatoid Arthritis
55 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Migraine Disorders
1 Actively Recruiting
Phase 3
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable
Mild pain
0 Actively Recruiting
Primary Dysmenorrhoea
1 Actively Recruiting
Not Applicable
Muscle Strain
0 Actively Recruiting
Sprains and Strains
0 Actively Recruiting
Pain
0 Actively Recruiting
Osteoarthritis
0 Actively Recruiting
Post Partum Pain
0 Actively Recruiting

Orudis Reviews: What are patients saying about Orudis?

5Patient Review
1/18/2012
Orudis for Rheumatoid Arthritis
I have Rheumatoid Arthritis, and I've been using this treatment for nearly 20 years. It works well for me, better than Viox or Celebrex ever did.
4.7Patient Review
10/23/2008
Orudis for Painful Periods
Orudis is excellent for menstrual cramps. I had results within thirty minutes of taking it and would recommend it to anyone with similar issues. The only downside is that it made me feel very sleepy.
4.3Patient Review
6/23/2008
Orudis for Joint Damage causing Pain and Loss of Function
I was prescribed this for my TMJ, but I've found it works better on arthritis than any other NSAID. It's easy to use; however, the directions are to take 6 pills three times a day, so it can be hard to keep track of how many you've taken.
2Patient Review
6/3/2008
Orudis for Joint Damage causing Pain and Loss of Function
I was prescribed this for a wrist sprain, but it only made the problem worse. I saw no relief after three days of treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about orudis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is orudis used for?

"This medication is an NSAID that works by blocking the production of natural substances that cause inflammation, helping to decrease swelling, pain, or fever."

Answered by AI

Is orudis still available?

"On August 24th, 2005, Wyeth sent a letter to the FDA informing them of the company's decision to stop manufacturing ORUDIS KT (ketoprofen) tablets. These were 12.5 mg tablets, and they were moved to the "Discontinued Drug Product List" section of the Orange Book."

Answered by AI

Why was orudis discontinued?

"Orudis KT is not available anymore because some studies found that it could possibly lead to a heart attack, stroke, irritation or bleeding in the stomach and intestines."

Answered by AI

What is the drug ketoprofen used for?

"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that can be used to relieve pain, inflammation, swelling, stiffness, and joint pain. This medicine requires a prescription from a doctor."

Answered by AI

Clinical Trials for Orudis

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Have you considered Orudis clinical trials? We made a collection of clinical trials featuring Orudis, we think they might fit your search criteria.Go to Trials
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Have you considered Orudis clinical trials? We made a collection of clinical trials featuring Orudis, we think they might fit your search criteria.Go to Trials
Image of UI Health Care Center for Advanced Reproductive Care in Iowa City, United States.

Ketorolac for Infertility Treatment

18 - 37
Female
Iowa City, IA
Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.
Phase 4
Recruiting
UI Health Care Center for Advanced Reproductive Care
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesDaniel ZachsSecondWave Systems Inc.
Have you considered Orudis clinical trials? We made a collection of clinical trials featuring Orudis, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security